Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Chi-Hsuan Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC. Hauptthemen laut MEDLINE: ErbB Receptors, Lung Neoplasms, Adenocarcinoma of Lung, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: National Science and Technology Council.
Abstract (Originalsprache)
In East Asia, epidermal growth receptor factor (EGFR) mutations are the most prevalent and important biomarkers for treating patients with advanced lung cancer. However, as L858R doublet mutations are rare, commercially available EGFR tests may yield false-negative results. To determine whether the L858R mutation of the L858R-K860I and L858R-L861F doublet mutations could be identified using different types of EGFR detection tests and to describe the clinical response of patients with lung cancer with L858R doublet mutations to EGFR tyrosine kinase inhibitors (TKI). Information and samples from four patients with L858R doublet mutations, including three with L858R-K860I and one with L858R-L861F, were retrospectively collected from the archives of our department. For each case, the clinical response to EGFR-TKI was retrieved from the medical records. Archived formalin-fixed paraffin-embedded blocks were subjected to Sanger sequencing, the cobas and Idylla EGFR tests, the IntelliPlex-LCP-DNA assay, and AmoyDx PLC panel. L858R mutations were all detected by Sanger sequencing and the Idylla EGFR test but missed by the cobas assay. The AmoyDx PLC detected L858R only in cases with L858R-K860I while the IntelliPlex-LCP-DNA assay detected L858R in the case with L858R-L861F. Additionally, three of the patients, who had measurable tumors, showed partial responses to afatinib and osimertinib. The L858R mutation associated with L858R-K860I and L858R-L861F doublet mutations could be detected using Idylla but not cobas EGFR tests. Using next-generation sequencing analysis should be considered after initial negative reports from the cobas test, because patients with L858R doublet mutations may benefit from EGFR-TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC.
- Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, ROC.
- PlexBio Co. Ltd, Neihu, Taipei, Taiwan, ROC.
- Department of Pathology, National Taiwan University Cancer Center, Taipei, Taiwan, ROC; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan, ROC; Graduate Institute of Pathology, National Taiwan…
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, ROC.
Förderung
- National Science and Technology Council
Zitieren
APA
Wu, C. H., Zhang, M. S., Huang, Y. L., Cheng, W. H., Lai, J. Y., Hsieh, M. S., & Liao, W. Y. (2024). Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155304
Vancouver
Wu CH, Zhang MS, Huang YL, Cheng WH, Lai JY, Hsieh MS, et al. Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155304
BibTeX
@article{Wu2024,
author = {Wu, Chi-Hsuan and Zhang, Man-San and Huang, Yen-Lin and Cheng, Wei-Hsiang and Lai, Jin-Yao and Hsieh, Min-Shu and Liao, Wei-Yu},
title = {Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155304}
}
EUVIMED